scholarly journals Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Arihant Jain ◽  
Lingaraj Nayak ◽  
Uday Prakash Kulkarni ◽  
Nikita Mehra ◽  
Uday Yanamandra ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Hematologic Malignancies ◽  
Hematologic Cancer

The Difference in the Incidence and the Trend of Malignant Lymphomas in Japan and the United States.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2695-2695
Author(s):  
Dai Chihara ◽  
Hidemi Ito ◽  
Tomohiro Matsuda ◽  
Akiko Shibata ◽  
Tomotaka Sobue ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Hematologic Malignancies ◽  
The United States ◽  
Cumulative Exposure ◽  
Malignant Lymphomas ◽  
Annual Percent Change ◽  
Percent Change ◽  
Nodular Sclerosis ◽  
The Us ◽  
The Difference

Abstract Abstract 2695 Background: Malignant lymphomas (ML) are heterogeneous groups that the detailed classification is evolving dramatically. An incidence of malignant disease in certain population reflects cumulative exposure to environment, genetics and their combination overtime. Therefore, a comparison of incidences in various population and their secular trends is very helpful to understand etiology of disease. The aim of this study is to assess the incidence and the trend of each ML subtypes and to evaluate the difference between Japan and US. Materials and Methods: We used the data from a population-based cancer registry in Japan and from the Surveillance Epidemiology and End Results (SEER) program 9. Registry data of the US, SEER 9 included 95,155 cases and the data of Japan included 48,658 cases. The period covered in this analyses was 1993 to 2006 in Japan and 1993 to 2008 in the US. Rates of sex-specific, age-standardized incidence with 95% confidence intervals were estimated and standardized by age-adjustment according to the world standard population. We also estimated the annual percent change using joinpoint regression analysis and evaluated the significance of the trend. Results: The overall age-standardized incidence rate of all malignant lymphomas per 100,000 in 2006 was 22.4 for males and 16.0 for females in the US, 7.4 for males and 4.9 for females in Japan. The incidence is higher in the US than Japan with most of the subtypes especially for the nodular sclerosis HL, CLL/SLL and FL. In general, B-cell lymphomas showed large difference in incidence while T-cell lymphomas (TCL) showed similar incidence between Japan and the US. The total numbers of ML are constantly increasing in Japan but not in the US as shown in the figure {annual percent change (95%CI), Japan; +2.6% (2.1, 3.1), US; +0.2% (−0.0, 0.4)}. As for details, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma and the total numbers of TCL are constantly increasing in both countries. Conclusion: In conclusion, we showed the marked difference in the incidence and the trend of hematologic malignancies between Japan and the US. The incidence of hematologic malignancies is lower in Japan than the US, but is increasing significantly. The most remarkable difference in the incidence was seen with nodular sclerosis HL, CLL/SLL and FL which was consistent with previous reports. Even with the TCL, the incidence seems to be similar to higher in the US except for the ATLL. The improvement in the quality of cancer registry systems and the organization of these registries between countries enables us to unite the data worldwide that will bring us new insights. Solid line and circle are the data of the US. Dashed line and hollow circle are the data of Japan. Disclosures: No relevant conflicts of interest to declare.

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1305-1305
Author(s):  
Aaron S Rosenberg ◽  
Ann M Brunson ◽  
Theresa HM Keegan ◽  
Joseph Tuscano ◽  
Ted Wun ◽  
...  
Keyword(s):  
Germ Cell ◽  
Primary Tumor ◽  
Hematologic Malignancies ◽  
Primary Site ◽  
Prognostic Impact ◽  
Primary Tumor Site ◽  
Men And Women ◽  
Risk Of Death ◽  
Hematologic Cancer ◽  
Prior Malignancy

Abstract Background: Multiple, small retrospective studies have suggested that ALL can occur as a secondary cancer, but the diagnosis of sALL remains controversial. Furthermore, its clinical significance remains poorly defined. Using population based data, we examined a large, retrospective cohort of patients with sALL to determine the risk factors for and prognostic impact of sALL compared to ALL without preceding cancer. Methods: Patients diagnosed with ALL during 1988-2012 were identified in the California Cancer Registry (CCR) (n=15,135). Cases were considered sALL if they were preceded by any other malignancy except primary acute leukemia, chronic myeloid leukemia, Burkitt leukemia/lymphoma, lymphoblastic lymphoma or non-hodgkin lymphoma, not otherwise specified. Non-menaloma skin cancer is not captured by CCR, and thus was not included considered a first malignancy. We determined standard incidence ratios (SIR) for sALL by comparing expected rates of ALL from the CCR to observed rates in patients with a previous malignancy. Hematologic malignancies and breast, thyroid and germ cell cancers were identified as potential high-risk patients in prior reports. SIRs for these tumors and for colorectal and prostate cancer, due to their frequency, were calculated. The effect of sALL, compared to primary ALL, on overall survival (OS) was estimated using Cox proportional hazards models accounting for age, sex, race, year of diagnosis, histology, neighborhood socioeconomic status (SES), marital status, and rural vs urban residence. Results: Secondary ALL accounted for 3.7% (n=566) of patients diagnosed with ALL in the CCR. Compared to primary ALL, sALL was more common in females (43% vs 55%, p<0.0001), non-Hispanic Whites (37% vs 62.9% p<0.0001), older patients (21% over the age of 40 vs 87%), more likely to be diagnosed in 2008-2012 than before (23% vs 31%, p<0.0001) and in patients residing in the highest two quintiles of SES (17% vs 22% p=0.002 and 16% vs 27% p<0.0001, respectively). The most common first primary tumor sites among sALL patients were breast (14%), male genital system (10%), lymphoma (8%), and digestive system (6.7%). The primary tumor site was unknown in 30% of cases. The SIRs of developing sALL are summarized in the Table. Of note, both men and women were more likely to develop ALL after a preceding malignancy than the background population, overall SIR 1.7 (95% CI 1.5 - 1.8), male SIR 1.4 (1.2 - 1.6), and female SIR 2.0 (1.8 - 2.4). While hematologic malignancies and endocrine/thyroid cancers increased the risk in men and women, germ cell tumors increased the risk of sALL only in men; expectedly breast cancer increased the risk only in women. Compared to primary ALL, the adjusted hazard ratio (aHR) of death for patients with sALL was 1.07 (0.96-1.18, p=0.2). A second model considered type of prior malignancy to sALL: hematologic malignancies, solid tumors with statistically significant SIRs >1 (breast, thyroid, and germ cell), and other tumors. Compared to primary ALL, patients with sALL after a prior hematologic malignancy had a significantly increased risk of death (aHR 1.38, 1.07 - 1.8), while those with prior breast/thyroid/germ cell (aHR 1.18, 0.95 - 1.46) or any other primary (aHR 1.12, 0.96 - 1.31) cancers did not. Conclusions: To our knowledge, this study represents the largest cohort of sALL reported to date, and establishes sALL as a clinically relevant subtype of ALL. Although the risk of developing sALL is increased for patients with any prior malignancy, only specific cancers provide excess risk. Furthermore, the risk of death was increased in sALL patients with a prior hematologic cancer. Our findings provide evidence that sALL is clinically distinct entity, and have implications for both survivorship of solid and hematologic cancer and risk stratification of ALL. Further study into the etiology of sALL, and the possibility that sALL is therapy related, is warranted. Table 1. SIRs by Primary Site and Gender Total Males Females Primary Site SIR 95% CI SIR 95% CI SIR 95% CI Any 1.7# (1.5 - 1.8) 1.4# (1.2 - 1.6) 2.0# (1.8 - 2.4) Solid tumor 1.4# (1.3 - 1.6) 1.1 (0.9 - 1.3) 1.8# (1.5 - 2.1) Hem 5.5# (4.3 - 7.0) 5.1# (3.6 - 7.0) 6.1# (4.1 - 8.7) Breast 1.8# (1.4 - 2.2) 0 (0 - 12.4) 1.8# (1.4 - 2.3) Colorectal 1.3 (0.8 - 1.8) 1.2 (0.6 - 1.9) 1.4 (0.4 - 2.4 Prostate 0.9 (0.7 - 1.2) 0.9 (0.7 - 1.2) 0 (0 - 0) Endocrine/Thyroid 3.0# (1.7 - 4.9) 3.9# (1.4 - 8.4) 2.6# (1.2 - 4.9) Germ Cell 2.4# (1.2 - 4.3) 3.6# (1.5 - 7.0) 1.3 (0.3 - 3.8) #:p<0.05 Disclosures Jonas: Onyx: Honoraria; Celgene: Honoraria; Incyte: Honoraria; GlycoMimetics: Consultancy.

Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data

2007 ◽  
Vol 18 (5) ◽  
pp. 561-569 ◽  
Author(s):  
Soko Setoguchi ◽  
Daniel H. Solomon ◽  
Robert J. Glynn ◽  
E. Francis Cook ◽  
Raisa Levin ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Cancer Registry ◽  
Hematologic Malignancies ◽  
Registry Data ◽  
Medicare Claims ◽  
Cancer Registry Data

Changes in the setting of first consults to palliative and supportive care over a 7-year period.

2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 86-86
Author(s):  
Bernard Lobato Prado ◽  
Ali Haider ◽  
Syed M. Naqvi ◽  
Roberto Carmagnani Pestana ◽  
Janet L. Williams ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Hematologic Malignancies ◽  
Outpatient Setting ◽  
Annual Number ◽  
Trend Test ◽  
Hematologic Cancer ◽  
Inpatient Settings ◽  
Armitage Trend Test ◽  
Changes Over Time ◽  
Over Time

86 Background: Optimal benefits from palliative cancer care (PC) are achieved when first consults (PC1) occur early, ideally in the outpatient setting. Late PC1, such as those occurring in the intensive care unit (ICU), limit the benefits of PC and are a poor indicator of the integration of PC and oncology. Our aim was to determine the proportion of PC1 over time in three clinical settings: outpatient clinic (OPC), ICU, and inpatient non-ICU (IP). We also examined patients’ demographic and clinical characteristics and the timing of PC access (from PC1 to death or last contact) by the setting of PC1. Methods: We evaluated consecutive administrative/billing records to ascertain the annual number of PC1 and its distribution across settings from 2011 to 2017. ICU PC1 (n = 309) and a random sample of an equal number of OPC and IP PC1 were reviewed to retrieve patients’ demographics, clinical characteristics, and date of death/last contact. The Cochran-Armitage trend test was used to determine trend differences in the proportion of PC1 among settings. Results: The total annual number of PC1 increased by 58% from 2011 (n = 2286) to 2017 (n = 3615). We found a significant decreasing trend in the proportion of PC1 at the ICU (from 2.3% in 2011 to 1% in 2017, p < 0.001). There were no significant changes over time in the proportion of PC1 at OPC versus inpatient settings (p = 0.2). Hematologic cancer patients were more likely to have a PC1 at the ICU (p < .001). PC1 at ICU accessed PC much later, median survival (95% CI) after PC1 in months: OPC= 7.7 (6.3 - 9.7); IP= 3.4, (2.4 - 4.5), ICU= 0.1 (0.1, 0.1), p < .01). Conclusions: Over time, the total annual number of PC1 has increased and the proportion of PC1 at ICU, a very late clinical setting, is decreasing. Further efforts are needed to promote early PC referrals for patients with hematologic malignancies.

scholarly journals Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth

2019 ◽  
Author(s):  
Kushani Shah ◽  
Robert H Whitaker ◽  
Theodore Busby ◽  
Jing Hu ◽  
Bi Shi ◽  
...  
Keyword(s):  
Cell Growth ◽  
Cancer Cell ◽  
Critical Role ◽  
Hematologic Malignancies ◽  
Cell Penetrating Peptides ◽  
H3k4 Methylation ◽  
Cancer Cell Growth ◽  
Hematologic Cancer ◽  
Binding Peptides ◽  
Binding Groove

DPY30 facilitates H3K4 methylation by directly binding to ASH2L in the SET1/MLL complexes and plays an important role in hematologic malignancies. However, the domain on DPY30 that regulates cancer growth is not evident, and the potential of pharmacologically targeting this chromatin modulator to inhibit cancer has not been explored. Here we have developed a peptide-based strategy to specifically target DPY30 activity. We have designed cell-penetrating peptides derived from ASH2L that can either bind to DPY30 or show defective or enhanced binding to DPY30. The DPY30-binding peptides specifically inhibit its activity in interacting with ASH2L and enhancing H3K4 methylation. Treatment with the DPY30-binding peptides significantly inhibited the growth of MLL-rearranged leukemia and other MYC-dependent hematologic cancer cells. We also revealed subsets of genes that may mediate the effect of the peptides on cancer cell growth, and showed that the DPY30-binding peptide sensitized leukemia to other types of epigenetic inhibitors. These results strongly support a critical role of the ASH2L-binding groove of DPY30 in promoting blood cancers, and demonstrate a proof-of-principle for the feasibility of pharmacologically targeting the ASH2L-binding groove of DPY30 for potential cancer inhibition.

Efficacy of a Transdermal Granisetron Patch in Controlling Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Cancer Patients

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3045-3045
Author(s):  
Ruben Niesvizky ◽  
Ana Fernández Velasco ◽  
Doris S Wong ◽  
Deborah Braccia
Keyword(s):  
Cancer Patients ◽  
Acute Phase ◽  
Rescue Medication ◽  
Hematologic Malignancies ◽  
Emetogenic Chemotherapy ◽  
Response To Therapy ◽  
Patient Assessment ◽  
Highly Emetogenic Chemotherapy ◽  
Hematologic Cancer ◽  
Delayed Phase

Abstract Introduction: Multiday, highly emetogenic chemotherapy regimens are commonly used in the management of hematologic malignancies. Despite progress in prophylaxis, CINV, especially during the delayed phase, can remain a significant barrier to attaining planned chemotherapy dose on time for some patients. A granisetron transdermal system (GTS) has been shown to be as effective as oral granisetron in controlling CINV across multiple tumor types. This post-hoc analysis specifically examined the efficacy and safety of GTS in patients with hematologic malignancies. Methods: A randomized, phase 3 study has been published comparing GTS (7 day application) to oral granisetron (2 mg/day) in patients receiving either moderately or highly emetogenic chemotherapy for 3-5 days. Data for this analysis were limited to patients with a primary tumor diagnosis of lymphoma (n=51), leukemia (n=27), or multiple myeloma (n=5). The rates of complete control (CC; no vomiting, mild nausea, no rescue medication) and complete response (CR; no vomiting, no rescue medication) using either GTS or oral granisetron were compared during both the acute (first 24 hours) and delayed phase (days 2 to 5) following chemotherapy. Need for rescue medication and patient assessment of response to therapy with GTS were also compared. Results: 83 hematologic cancer patients (31 GTS, 52 oral granisetron) were included. The majority of patients received a non-cisplatin regimen with corticosteroids (59 patients; 71%). Patients received chemotherapy for 3 days (37; 45%) or 4 to 5 days (46 patients; 55%). During the acute phase of CINV, the CC rate of 94% and CR rate of 94% in the GTS group were similar to rates in the overall population (94% and 95%, respectively). There was no difference in CC and CR between GTS and oral granisetron in the acute phase (P=0.90 and 0.59, respectively). In the delayed phase, GTS resulted in CC in 87% and CR in 90%; compared with CC in 77% and CR in 81% of patients given oral granisetron (P=0.26 and 0.25, respectively). The use of rescue medication over the entire study period and patient assessment of overall response to therapy were not different between arms (P=0.60 and 0.92, respectively). GTS was well tolerated; the only treatment related adverse event was one case of mild constipation. Conclusion: This retrospective analysis suggests GTS may be an appropriate option for prevention of CINV in hematologic cancer patients. A trend toward improved control in the delayed phase was observed and further investigation of a benefit in delayed CINV for hematologic malignancies may be warranted. Disclosures Fernández Velasco: ProStrakan: Employment. Wong:ProStrakan: Employment. Braccia:ProStrakan: Employment.

Synchronous and metachronous cases of renal cell carcinoma and hematologic malignancies in a state cancer registry.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 593-593
Author(s):  
John Clark Henegan ◽  
Katelyn Mitchell ◽  
Joseph Maher
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Hodgkin Lymphoma ◽  
Cancer Registry ◽  
Renal Cell ◽  
Hematologic Malignancies ◽  
Lymphocytic Leukemia ◽  
Future Research ◽  
P Value ◽  
Chi Square

593 Background: A Swedish national family-cancer database reported an association between renal cell carcinoma (RCC) and hematologic malignancies within families. Our hypothesis was that a search of a state cancer registry would detect an increased incidence of observed (versus expected) synchronous and metachronous cases of RCC and select hematologic malignancies. Methods: A query of the Mississippi Cancer Registry was performed for synchronous ( < 6 months between diagnoses) and metachronous ( > 6 months) cases of RCC and select hematologic malignancies (non-Hodgkin lymphoma (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, and Hodgkin lymphoma) in the state from 2003 to 2013. The expected number of cases was calculated based on crude case numbers available from https://www.cancer-rates.info/ms/. The percentage of the population < 18 years of age was removed from the eligible population. 2x2 tables were constructed to calculate a chi-square score of expected versus observed cases. Using one degree of freedom, a p-value was calculated from this statistic. Due to privacy issues, the registry was unable to provide an exact number of observed combined cases if there were < 5 in the time period. Results: Conclusions: There is a statistically significantly increased incidence of observed (versus expected) synchronous and metachronous cases of RCC with the B-cell malignancies NHL, MM, and CLL in Mississippi between 2003 and 2013. Future research will focus on clinical characteristics of patients with synchronous or metachronous cases of RCC and these hematologic malignancies.[Table: see text]

scholarly journals Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Emese Tolnai ◽  
Gábor Fidler ◽  
Róbert Szász ◽  
László Rejtő ◽  
Kingsley Okechukwu Nwozor ◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Fungal Infections ◽  
Area Under The Curve ◽  
Biological Indicators ◽  
Hematologic Malignancies ◽  
Characteristic Analysis ◽  
Gene Expressions ◽  
Oncology Patients ◽  
Hematologic Cancer ◽  
Pilot Clinical Study

Abstract Fungal infections represent a worrisome complication in hematologic cancer patients and in the absence of disease specific symptoms, it is important to establish new biological indicators, which can be used during mould-active prophylaxis. Recently, miRNAs have appeared as candidate diagnostic and prognostic markers of several diseases. A pilot clinical study was performed to evaluate the diagnostic utility of 14 microRNAs which can be related to invasive fungal infections. Based on our data miR-142-3p, miR-142-5p, miR-26b-5p and miR-21-5p showed significant overexpression (p < 0.005) due to invasive aspergillosis in hemato-oncology patients with profound neutropenia. A tetramiR assay was designed to monitor peripheral blood specimens. Optimal cut-off was estimated by using the median value (fold change 1.1) of the log10 transformed gene expressions. The biomarker panel was evaluated on two independent sample cohorts implementing different antimicrobial prophylactic strategies. The receiver operating characteristic analysis with area under the curve proved to be 0.97. Three miRNAs (miR-142-5p, miR-142-3p, miR-16-5p) showed significant expression alterations in episodes with sepsis. In summary, the tetramiR assay proved to be a promising diagnostic adjunct with sufficient accuracy and sensitivity to trace invasive aspergillosis in hemato-oncology patients.

scholarly journals Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study

2020 ◽  
Author(s):  
Majid Sorouri ◽  
Amir Kasaeian ◽  
Helia Mojtabavi ◽  
Amir Reza Radmard ◽  
Shadi Kolahdoozan ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Hematologic Malignancies ◽  
Cancer History ◽  
Clinical Indicators ◽  
Female Ratio ◽  
Risk Of Death ◽  
Hematologic Cancer ◽  
Increased Risk ◽  
History Of ◽  
History Of Cancer

Abstract Background: COVID-19 has caused great concern for patients with underlying medical conditions. We aimed to determine the prognosis of patients with current or previous cancer with either a PCR-confirmed COVID-19 infection or a probable diagnosis according to chest CT scan.Methods: We conducted a case control study in a referral hospital on confirmed COVID-19 adult patients with and without a history of cancer from February25th to April21st, 2020. Patients were matched according to age, gender, and underlying diseases. Demographic features, clinical and Para clinical data have been extracted from medical records. Multivariable logistic regression was used to estimate odd ratios and 95% confidence intervals of each factor of interest with outcomes. Results: Fifty-three confirmed COVID-19 patients with history of cancer were recruited and compared with 106 non-cancerous COVID-19 patients. Male to female ratio was 1.33 and 45% were older than 65. Dyspnea was significantly associated with an increased rate of mortality in the cancer subgroup (p=0.013). Twenty-six patients (49%) survived among the cancer group while 89 patients (84%) survived in control (p=0.000). Patients with hematologic cancer had 63% mortality while those with solid tumors had 37%. Multivariate analysis showed that cancer, impaired consciousness, tachypnea, tachycardia, leukocytosis and thrombocytopenia were associated with an increased risk of death.Conclusion: Cancer increased mortality rate and hospital stay of COVID-19 patients and remained significant after adjustment of confounders. Compared to solid tumors, hematologic malignancies have been associated with worse consequences and higher mortality. Clinical and Para clinical indicators were not appropriate to predict death.

scholarly journals Therapeutic Education and Physical Activity to Support Self-management of Cancer-related Fatigue in Hematologic Cancer Patients: Protocol of a Feasibility Randomized Controlled Trial

2020 ◽  
Vol 19 ◽  
pp. 153473542096983
Author(s):  
Monica Denti ◽  
Monia Allisen Accogli ◽  
Stefania Costi ◽  
Stefania Fugazzaro
Keyword(s):  
Physical Activity ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Hematologic Malignancies ◽  
Therapeutic Education ◽  
Self Management ◽  
Convenience Sample ◽  
Randomized Controlled ◽  
Cancer Related Fatigue ◽  
Hematologic Cancer

Introduction Hematologic malignancies account for nearly 8% of new cancer diagnosis in Italy. Cancer-related fatigue (CRF) is one of the most distressing symptoms reported by patients with cancer. As CRF has a multifactorial etiology, physical activity and therapeutic education may be beneficial for managing CRF, both during and after cancer treatment. However, there is a lack of evidence specific to hematologic malignancies. This paper describes the protocol of a feasibility study on Therapeutic Education and Physical Activity (TEPA) intervention to support self-management of CRF in patients with hematologic malignancies. Methods TEPA was addressed to newly diagnosed adult individuals with hematologic malignancy able to take part in a rehabilitation programme at the AUSL-IRCCS of Reggio Emilia. The protocol was developed in 2 phases. Phase I was an observational cohort study involving a convenience sample of 10 participants with the aim to evaluate the feasibility of the assessment schedule and to register longitudinal clinical data regarding CRF (FACIT-F), psychologic distress (NCCN Distress Thermometer), QoL (EORTC QLQ-C30), physical performance (TUG and 6MWT) and habitual level of physical activity during first months after diagnosis. Phase II (underway) is a feasibility randomized controlled trial (TEPA) involving a convenience sample of 40 participants and comparing 2 parallel active interventions (Therapeutic Education versus Therapeutic Education and Physical Activity) on top of usual care. The primary aim is to estimate the feasibility of TEPA, measured by the adherence rate to the intervention. Secondary aims are: to estimate the effect size of TEPA in terms of changes in CRF, psychological distress, QoL, physical performance and habitual level of physical activity (measured as in Phase I); to collect patient satisfaction, perception of usefulness of the TEPA intervention and data on long-term adherence to an active lifestyle. Data are collected in both phases at the time of diagnosis and then at 1-, 3- (completion of intervention) and 7-month follow-up. Discussion Data on feasibility and effect size of TEPA will be analyzed upon completion of Phase II, allowing us to design a large, adequately powered RCT to verify the effectiveness of this intervention on CRF management in patients with hematologic cancer. Trial registration: clinicaltrials.gov; Trial registration number: NCT03403075

Sign in / Sign up

Export Citation Format

Share Document